Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127155 | 0.89 | BRD4 (0.53) | BRD4BRD9L3MBTL1CYP2A13FGFR1 | |
| SCHEMBL415624 | 0.85 | DRD2 (0.51) | BRD4BRD9DRD2DRD3HRH1 | |
| SCHEMBL416499 | 0.83 | KDM4E (0.41) | BRD4BRD9DRD2DRD3DRD4 | |
| SCHEMBL414567 | 0.83 | NCF1 (0.58) | BRD4BRD9DRD2DRD3DRD4 | |
| SCHEMBL14355869 | 0.81 | CYP2A13 (0.58) | DRD2DRD3DRD4HRH2HRH1 | |
| SCHEMBL415676 | 0.79 | DRD4 (0.55) | DRD2DRD3DRD4L3MBTL1POLB | |
| SCHEMBL3436474 | 0.78 | AKR1C3 (0.61) | DRD2DRD3KDM1ACYP2A13ADRA1A | |
| SCHEMBL16573967 | 0.78 | LIPG (0.52) | BRD4BRD9L3MBTL1 | |
| SCHEMBL3730392 | 0.78 | CYP2A13 (0.67) | L3MBTL1CYP2A13CYP2D6HRH3 | |
| SCHEMBL1239635 | 0.76 | TAAR1 (0.45) | BRD4BRD9L3MBTL1CYP2A13FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | BRD4 244/4885BRD9 731/4885DRD2 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.